[Afternoon session of the first day of the 2026 National Talks: Representatives from Hengrui Pharmaceuticals, Dongguang Pharmaceutical, Pfizer and other companies entered the venue to start negotiations on chronic disease varieties] The reporter learned from the on-site negotiation of the 2026 National Medical Insurance Catalog and the price negotiation of the commercially insured innovative drug catalog that the afternoon session of the first day of the National Talks started at about 13:00 today. Reporters observed at the scene that negotiators from Hengrui Pharmaceuticals, Dongguang Pharmaceutical, Pfizer, Novo Nordisk, Tonghua Jinma and other companies successively arrived at the National People's Congress Conference Center in Beijing and entered the venue one after another after accepting identity verification. According to incomplete statistics from reporters, about 20 companies participated in negotiations during the afternoon session. Among them, Dongguangguang Pharmaceutical’s ologliflozin and hepatitis C combination drugs natansvir phosphate and icofosbuvir tablets, Pfizer’s new dual-indication drug for weight loss and diabetes, enoglutide injection and ogaituzumab for injection, and Tonghua Jinma’s new Alzheimer’s disease drug Aviacridine succinate tablets have all passed the preliminary review, which also means that innovative drugs and chronic disease drugs have begun intensive negotiations. (Reporters Lu Afeng and Yu Miao)